The Gene Therapy Transformation: A Guide for Managed Care Decision Makers

Reserve your spot today for this Virtual Satellite Symposium!

Jointly provided by
    Impact Education, LLC
This activity is supported by independent educational grants from bluebird bio and BioMarin.
Monday, October 19, 2020
11:00 AM - 12:30 PM ET

Don't miss our current activities at

  Learn About
  • The principles of gene therapy in the treatment of rare diseases
  • Latest clinical trial updates
  • Financial implications of gene therapy and potential payment models for appropriate use
  Expert Faculty Presenters
John Petrich, RPh, MS
Manager, Investigational Drug Service
Cleveland Clinic
Edmund Pezalla, MD, MPH
Enlightenment Bioconsult, LLC
Mari-Pat Pusey, MBA
Senior Product Director
  Who Should Attend?

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending AMCP Nexus 2020 virtually.

  Statement of Need/Program Overview

Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under investigation to ensure safety and efficacy. Furthermore, research in this field is particularly challenging given the inherent nature of rare diseases and genetic disorders. Approximately 30 million individuals in the United States are living with a rare disease, which by definition have a prevalence of 200,000 or fewer cases in the United States.

Genetic disorders and other rare diseases present unique challenges for health insurers in terms of requisite clinical intervention, disease management, and economic burden. The treatment landscape in US health care has already evolved significantly over the past several decades and appears to be on the precipice of its most groundbreaking innovation to date: gene therapy. This program is designed to address the educational needs for payers and managed care professionals regarding the solutions necessary to address the unique clinical and financial considerations surrounding gene therapies that will ensure quality care and appropriate patient access.

  Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Explain the molecular and physiologic principles of gene therapy in the treatment of rare diseases
  • Review outcomes measures for clinical trials in gene therapy and the pertinent clinical trial data for investigational treatments
  • Evaluate the financial implications of gene therapy in terms of acquisition costs reconciled with the potential for improved outcomes and reduced health care service utilization
  • Assess current and proposed payment models aligned with appropriate use for high-cost therapies

Date and Time
Monday, October 19, 2020
11:00 AM - 12:30 PM

11:00 AM Pre-Activity Learning Assessment and Opening Comments/Overview
Mari-Pat Pusey, MBA
11:05 AM Principles of Gene Therapy and Measurement of Clinical Outcomes
John Petrich, RPh, MS
11:35 AM Assessing the Curative Benefits of Gene Therapy in a Cost Conscious Environment
Edmund Pezalla, MD, MPH
11:55 AM Medical and Pharmacy Management Strategies for Optimal Gene Therapy Outcomes
Mari-Pat Pusey, MBA
12:15 PM Audience Q&A Session
12:25 PM Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation
12:30 PM Adjournment
  Accreditation Information
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-20-2296-L01-P
Type of Activity: Application

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

If you have any questions, please call (215) 619-8812 or email